Cytosorbents (CTSO) Cash from Operations Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 185.96% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 122.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 16.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 66.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.47% |
| Dec 31, 2025 | -106.11% |
| Sep 30, 2025 | -4.63% |
| Jun 30, 2025 | 68.52% |
| Mar 31, 2025 | 28.24% |
| Dec 31, 2024 | 63.46% |
| Sep 30, 2024 | 52.69% |
| Jun 30, 2024 | 30.85% |
| Mar 31, 2024 | -55.39% |
| Dec 31, 2023 | -19.98% |
| Sep 30, 2023 | 22.70% |
| Jun 30, 2023 | 13.77% |
| Mar 31, 2023 | 61.72% |
| Dec 31, 2022 | 2.75% |
| Sep 30, 2022 | -62.93% |
| Jun 30, 2022 | -294.84% |
| Mar 31, 2022 | -246.35% |
| Dec 31, 2021 | -419.15% |
| Sep 30, 2021 | -25.86% |
| Jun 30, 2021 | -205.06% |